COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus

Infect Dis Clin North Am. 2022 Jun;36(2):397-421. doi: 10.1016/j.idc.2022.01.006. Epub 2022 Feb 1.

Abstract

This review describes the incidence, epidemiology, and risk factors for mortality of COVID-19 in immunocompromised patients, including persons with human immunodeficiency virus. It describes various preventive measures, including vaccines and their effectiveness and the role of monoclonal antibodies for pre-exposure prophylaxis. It also reviews the different treatment options for immunocompromised individuals, including antivirals, monoclonal antibodies, and immunomodulators. Lastly, it describes the impact of COVID-19 on transplantation and continuity care of this population.

Keywords: CD4; COVID-19; HIV; Hematopoietic stem cell transplant; Immunocompromise; Immunosuppression; SARS-CoV-2; Solid organ transplant.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • COVID-19*
  • HIV
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Humans
  • Immunocompromised Host

Substances

  • Antibodies, Monoclonal